🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Arvinas, Inc. ARVN R2K

Healthcare · Biotechnology · United States
https://www.arvinas.com

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

READ MORE ›
$8.98
+24.72% 1Y

Market & Price

Market Cap
$579.40M
Current Price
$8.98
High / Low (52W)
$13.83 / $6.24
Beta
1.80

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$6.00
Price to Book
1.50
P/S
6.48
EV/EBITDA
0.11
Dividend Yield
-

Profitability & Returns

ROCE
-20.59%
ROE
-42.28%
ROA
-18.92%
Profit Margin
-
Op Margin
-
EPS (Latest Qtr)
$-0.90
EPS (TTM)
$-3.18

Balance Sheet & Liquidity

Debt/Equity
2.17
Quick Ratio
5.36
Current Ratio
5.44
Debt
$8.40M
Total Assets
$717.90M
Current Assets
$700.70M
Working Capital
$558.20M

Ownership

Promoter Holding
7.76%
Chg in Prom Hold
-0.00%
FII / Inst Holding
83.29%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$-27.10M
Total Revenue (TTM)
$89.40M
EBITDA
$-246.50M
Free Cash Flow
$-199.64M
Operating Cash Flow
$-254.10M
Shares Outstanding
64.52M
Gross Margin
-
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
25.96%
Profit 5Y
23.80%
Revenue (YoY)
-91.70%
Earnings (YoY)
-

PROS

  • Compounding revenue at 26.0% over 5 years.
  • Profit CAGR of 23.8% over 5 years.

CONS

  • Trading 35.1% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ARVN Arvinas, Inc. R2K 8.98 - $579.40M - -20.59% -42.28% 25.96% 23.80%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
⚙Ad space

Quarterly Results

Figures in USD.

Metric Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --------4.00M---6.20M--5.50M------------188.80M22.40M41.90M9.50M15.60M
Cost of Revenue ---------------------------------
Gross Profit ---------------------------------
Operating Expenses ----------------------------117.40M93.90M85.70M84.10M79.40M
Operating Income -6.32M-6.72M-6.41M-5.31M-4.28M-8.52M-14.06M-16.94M-15.81M-18.42M5.50M-22.79M-23.41M-26.48M-31.75M-41.70M-51.90M-47.30M-57.70M-65.80M-64.30M-87.70M-74.60M-73.90M-83.30M-48.50M--71.40M-71.50M-43.80M-74.60M-63.80M
EBITDA ----------------------------72.70M-70.10M-42.50M-73.40M-62.70M
Interest Expense ---------------------------------
Pretax Income ----------------------------83.10M-61.50M-34.80M-67.20M-57.50M
Tax Provision ----------------------------200.00K-300.00K300.00K200.00K100.00K
Net Income -6.25M-6.68M-6.40M-4.73M-4.15M-7.85M-13.39M-16.09M-14.40M-17.16M-17.68M-21.05M-21.74M-25.23M-30.82M-41.00M-50.30M-46.80M-63.40M-70.00M-66.20M-81.90M-66.60M-64.00M-69.40M-35.20M--82.90M-61.20M-35.10M-67.40M-57.60M
Diluted EPS ----------------0.84-1.03-0.94-1.20-1.32-1.24-1.54-1.25-1.18-0.97-0.49--1.14-0.84-0.48-1.10-0.90
R&D Expense 7.06M7.82M7.22M6.69M7.14M10.34M13.15M14.56M14.19M16.00M16.59M20.41M21.73M23.42M30.01M34.90M43.00M40.60M64.00M75.30M77.50M95.30M103.40M85.90M84.30M93.70M86.90M-90.80M68.60M64.70M-60.30M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -14.30M18.30M21.80M-131.40M78.50M263.40M262.60M
Cost of Revenue ---------
Gross Profit ---------
Operating Expenses -----394.60M480.00M513.60M381.10M
Operating Income -24.76M-43.80M-51.50M-120.80M--263.20M-401.50M-250.20M-118.50M
EBITDA ------255.00M-394.80M-243.60M-113.30M
Interest Expense ----100.00K----
Pretax Income ------251.00M-363.90M-198.30M-80.50M
Tax Provision -----20.90M900.00K600.00K300.00K
Net Income -24.05M-41.48M-70.30M-119.30M--282.50M-367.30M-198.90M-80.80M
Diluted EPS ---2.13-3.02-3.82-5.31-6.62-2.77-
R&D Expense 28.79M45.19M67.20M108.40M180.40M315.00M379.70M348.20M285.20M

Compounded Sales Growth

5 Years:25.96%
1 Year:-91.70%

Compounded Profit Growth

5 Years:23.80%
1 Year:-

Stock Price Performance

1 Year:+24.72%
6 Months:-25.91%
3 Months:-32.33%
1 Month:-8.55%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -66.85M199.28M301.64M717.40M-1.27B1.30B1.09B717.90M
Current Assets ------1.24B1.28B1.07B700.70M
Cash & Equivalents -30.91M3.19M9.21M588.40M-81.30M311.70M100.50M142.90M
Inventory ----------
Receivables ------1.00M05.70M1.00M
Total Liabilities -66.60M62.61M74.96M75.20M-703.90M644.60M529.80M284.10M
Current Liabilities -17.85M22.98M32.81M49.20M-295.10M257.10M229.80M142.50M
Long Term Debt -151.12K2.00M2.00M2.00M-1.00M800.00K600.00K400.00K
Total Debt ------5.50M3.20M9.70M8.90M
Total Equity -32.88M-61.23M136.60M226.60M642.20M-564.90M660.00M561.60M433.80M
Shares Outstanding ------53.20M68.00M68.80M73.50M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 5.11M-16.12M-40.60M-89.70M--273.50M-347.80M-259.30M-273.80M
Investing Cash Flow 20.87M-179.67M-93.10M164.30M-242.80M203.50M34.70M407.60M
Financing Cash Flow -161.36K168.06M139.70M504.60M-4.70M374.70M7.90M-91.40M
Capital Expenditure -1.01M-2.83M-6.30M-6.40M--6.80M-2.90M-1.80M-1.90M
Free Cash Flow 4.10M-18.95M-46.90M-96.10M--280.30M-350.70M-261.10M-275.70M
Net Change in Cash ------26.00M230.40M-216.70M42.40M
Share Buybacks ------0091.90M

Ratios (Annual)

Figures in %.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ---------
Operating Margin % --306.3%-281.4%-554.1%--200.3%-511.5%-95.0%-45.1%
Net Margin % --290.1%-384.2%-547.2%--215.0%-467.9%-75.5%-30.8%
ROE % 39.3%-30.4%-31.0%-18.6%--50.0%-55.7%-35.4%-18.6%
ROCE % -50.5%-24.8%-19.2%-18.1%--27.0%-38.3%-29.0%-20.6%

Shareholding Pattern

Insiders
7.76%
Institutions
83.29%
Public Float
90.30%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 10.54% 6.80M $61.04M
2 Vanguard Portfolio Management LLC 6.03% 3.89M $34.93M
3 Shaw D.E. & Co., Inc. 5.64% 3.64M $32.67M
4 Pfizer Inc 5.36% 3.46M $31.05M
5 Vanguard Capital Management LLC 4.17% 2.69M $24.15M
6 TCG Crossover Management, LLC 3.70% 2.39M $21.44M
7 Armistice Capital, LLC 3.07% 1.98M $17.76M
8 Two Sigma Investments, LP 2.84% 1.83M $16.45M
9 State Street Corporation 2.83% 1.83M $16.42M
10 Geode Capital Management, LLC 2.41% 1.56M $13.98M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ARVN

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space